| Literature DB >> 35141048 |
Qun Wang1,2, Shengqian Dou1,2, Bin Zhang1,2, Hui Jiang1,2, Xia Qi1,2, Haoyun Duan1,2, Xin Wang1,3, Chunxiao Dong1,3, Bi Ning Zhang1,2, Lixin Xie1,2, Yihai Cao4, Qingjun Zhou1,2, Weiyun Shi1,3.
Abstract
The corneal endothelium is critical for maintaining corneal clarity by mediating hydration through barrier and pump functions. Progressive loss of corneal endothelial cells during aging has been associated with the development of Fuchs endothelial corneal dystrophy (FECD), one of the main causes of cornea-related vision loss. The mechanisms underlying FECD development remain elusive. Single-cell RNA sequencing of isolated healthy human corneas discovered 4 subpopulations of corneal endothelial cells with distinctive signatures. Unsupervised clustering analysis uncovered nuclear enriched abundant transcript 1 (NEAT1), a long non-coding RNA (lncRNA), as the top expressed gene in the C0-endothelial subpopulation, but markedly downregulated in FECD. Consistent with human corneas, a UVA-induced mouse FECD model validated the loss of NEAT1 expression. Loss of NEAT1 function by an in vivo genetic approach reproduced the exacerbated phenotype of FECD by ablating corneal endothelial cells. Conversely, gain of function by a CRISPR-activated adenoviral delivery system protected corneas from UVA-induced FECD. Our findings provide novel mechanistic insights into the development of FECD, and targeting NEAT1 offers an attractive approach for treating FECD.Entities:
Keywords: CRISPR-activated delivery system; Fuchs endothelial corneal dystrophy; corneal endothelium; lncRNA NEAT1; single-cell transcriptome
Year: 2022 PMID: 35141048 PMCID: PMC8807987 DOI: 10.1016/j.omtn.2022.01.005
Source DB: PubMed Journal: Mol Ther Nucleic Acids ISSN: 2162-2531 Impact factor: 8.886
Figure 1Construction of human corneal endothelium atlas by scRNA-seq
(A) Flowchart of the experiments performed in this study. (B) t-SNE clustering of human corneal endothelial cells colored by 4 distinct clusters. (C) Heatmap for expression of differentially expressed genes (DEGs) in each subtype. (D) Representative GO terms of all DEGs in each cell type. (E) Expression of representative marker genes across clusters. (F) Definition and surface phenotype of “effector cells.” (G) Expression of top markers in “effector cells.” (H) Representative novel markers of C1–C3 cells.
Figure 2Histological analysis of representative genes in C2 and C3 clusters
(A) t-SNE clustering of human corneal endothelial cells colored by cell-cycle phases. (B) Proportion of cell-cycle stages per cluster. (C) Percentage of mitochondrial genes in each cell cluster. ∗∗∗∗p < 0.0001 (2-sided Wilcoxon rank-sum tests). (D) Density plot showing the cell distribution with different SASP scores across cell clusters. (E) Immunohistochemical staining of PCNA validated the presence of C2 cluster in endothelium sections of human cornea. The PCNA+ cells in limbus are indicated by black arrows. (F) Immunofluorescence analysis of IL-11 showing the C3 cells in human cornea endothelium tissues.
Figure 3Transcriptional characteristics of 4 endothelial cell subtypes
(A) Representative GO terms of all DEGs between C0 and C1 cells. (B) Immunofluorescence analysis of ITGA6 showing C1 cells in the human cornea endothelium. (C and D) Gene scoring analysis using curated molecular signatures for endothelial functions (C) and metabolic process (D). ∗∗p < 0.01; ∗∗∗∗p < 0.0001 (2-sided Wilcoxon rank-sum tests).
Figure 4Downregulation of lncRNA NEAT1 in FECD
(A) Gene expression enrichment scores for FECD-associated genes. (B) Signature score of FECD-associated genes across 4 clusters. (C) Heatmap of differentially expressed lncRNA in FECD RNA-seq. (D) lncRNA NEAT1 IGV tracks showing significantly downregulated expression of 2 isoforms between normal and FECD libraries. (E) Boxplot of normalized counts of lncRNA NEAT1 in RNA-seq. (F) qPCR verified the downregulation of lncRNA NEAT1 (n = 4). ns, not significant; ∗p < 0.05; ∗∗p < 0.01; ∗∗∗∗p < 0.0001 (2-tailed t test).
Figure 5Knockdown (KD) of Neat1 expression in the mouse corneal endothelium and in human corneal endothelial cells
(A) Experimental timeline including intracameral injection of rAAV and FECD model construction. rAAV 4wk: UVA irradiation 4 weeks post-injection of virus. (B) Representative confocal images of whole mount of corneal endothelium detecting ZO-1 treated with control shRNA (NC) and Neat1 shRNA (Neat1 KD) in normal and FECD mouse. Scale bars, 50 μm. (C) ZO-1 immunostaining-based analysis for cell density, hexagonality, and coefficient of variation (n = 3). (D) Representative OCT images of mouse corneas at 3 months post-UVA. (E) OCT image-based CCT analysis from pre-UVA to 3 months post-UVA. n = 3 for each group. (F) Cell viability of HCEC upon NEAT1 KD with or without H2O2 treatment. (G) Mitochondrial abundance by comparative quantitative real-time-PCR upon KD of NEAT1. (H) Cellular ROS levels in NEAT1 KD HCEC upon H2O2 treatment. Quantitative data are shown as means ± SEs, n = 3. ns, not significant; ∗p < 0.05; ∗∗p < 0.01; ∗∗∗p < 0.001; and ∗∗∗∗p < 0.0001 (2-tailed t test).
Figure 6Neat1 overexpression attenuates oxidative damage in mouse corneal endothelium during FECD pathogenesis
(A) Neat1-targeting CRISPR-dCas9 activation system. (B) ZO-1 staining showed the corneal endothelium morphology after Neat1 overexpression during FECD. Scale bars, 50 μm. sg-NC, sgRNA− control; sg-Neat1, sgRNA-Neat1. (C) Coefficient of variation analysis from mouse corneal endothelium treated with sg-NC and sg-Neat1 rAAV (n = 3). (D) Comparison of OCT images from sg-NC, sg-Neat1, and NAC-treatment FECD mice. (E) Statistical analysis was used to analyze the effects of Neat1 and NAC treatment on CCT changes. n = 6 for each group. The red asterisk represents the difference between the sg-NC and NAC-treatment groups; the blue asterisk represents the difference between the sg-NC and sg-Neat1 groups; The black represents the difference between the sg-Neat1 and NAC groups. ∗p < 0.05; ∗∗p < 0.01; ∗∗∗p < 0.001; ∗∗∗∗p < 0.0001; ns, not significant (2-tailed t test).